European Oncology Attracts Big Pharma

European Oncology Attracts Big Pharma

Snapshot by Mergermarket

Jon Smith of Mergermarket, one of the investment banking industry’s go-to publications, references expert comment from Ali Pashazadeh, Treehill Partners CEO, on European oncology biotechs attracting Big Pharma interest. Ali discusses why the new generation of reduced toxicity ADCs are one of the hottest topics, and combination therapies with immune checkpoint inhibitors, especially with Keytruda coming off patent. He also discusses how markets have affected combination treatments in comparison to monotherapies, and dealing with the impact of the backlog of European companies needing to raise cash extending to 2-3 years. Well worth a read: (free of charge sign-up required).

Subscribe to our mailings!

Thank You

Please choose your subscriptions:

Unsubscribe any time using the footer of our emails. For information about our privacy practices, please visit our privacy policy.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Leave a Reply